Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-14
2011-06-14
Hartley, Michael G (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07960424
ABSTRACT:
The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
REFERENCES:
patent: 4695578 (1987-09-01), Coates et al.
patent: 4753789 (1988-06-01), Tyers et al.
patent: 4886808 (1989-12-01), King
patent: 4906755 (1990-03-01), Gittos
patent: 4929632 (1990-05-01), Tyers et al.
patent: 4937247 (1990-06-01), King
patent: 5011846 (1991-04-01), Gittos et al.
patent: 5034398 (1991-07-01), King
patent: 5202333 (1993-04-01), Berger et al.
patent: 5240954 (1993-08-01), Tyers et al.
patent: 5272137 (1993-12-01), Blase et al.
patent: 5344658 (1994-09-01), Collin
patent: 5578628 (1996-11-01), Tyers et al.
patent: 5578632 (1996-11-01), Tyers et al.
patent: 5622720 (1997-04-01), Collin
patent: 5854270 (1998-12-01), Gambhir
patent: 5922749 (1999-07-01), Tyers et al.
patent: 5955488 (1999-09-01), Winterborn
patent: 6063802 (2000-05-01), Winterborn
patent: 6284749 (2001-09-01), Castillo et al.
patent: 6287592 (2001-09-01), Dickinson
patent: 6294548 (2001-09-01), James
patent: 2001/0020029 (2001-09-01), James
patent: 2003/0095926 (2003-05-01), Dugger, III
patent: WO 03/100091 (2003-12-01), None
patent: WO-2004045615 (2004-06-01), None
patent: W02004067005 (2004-08-01), None
patent: WO-2004073714 (2004-09-01), None
Matsumoto et al., “Yakuzaigaku Manual”, 1st edition, Nanzando Co., Ltd. (1989) 2 pages.
Barton (Citrate Buffer Calculation, 2000, 2pgs.
Eglen, R. M. et al., Pharmacological Characterization of RS 25259-197, a Novel and Selective 5-HT3Receptor Antagonist, in vivo, extracted fromBritish Journal of Pharmacology, 1995, vol. 114, No. 4, pp. 860-866.
Chelly, Jacques et al., Oral RS-25259 Prevents Postoperative Nausea and Vomiting Following Laparoscopic Surgery, extracted fromAnesthesiology, 1996, vol. 85, No. 3A, p. A21.
Sorbe, Bengt, 5-HT3Receptor Antagonists as Antiemetic Agents in Cancer Chemotherapy, extracted fromExpert Opinion on Investigational Drugs, 1996, vol. 5, No. 4, pp. 389-407.
Gaster, Laramie M. and King, Frank D., Serotonin 5-HT3and 5-HT4Receptor Antagonists, extracted fromMedicinal Research Reviews, 1997, vol. 17, No. 2, pp. 163-214.
Tang, Jun et al., Efficacy of RS-25259, a Novel 5-HT3Antagonist, in the Prevention of Postoperative Nausea and Vomiting After Major Gynecologic Surgery, abstract extracted fromAnesthesiology, 1997, vol. 85, No. 3, suppl. p. A329.
Tang, Jun et al., The Efficacy of RS-25259, a Long-Acting Selective 5-HT3Receptor Antagonist, for Preventing Postoperative Nausea and Vomiting After Hysterectomy Procedures, extracted fromAnesthesia and Analgesia, 1998, vol. 87, pp. 462-467.
Adis R&D Profile, Palonosetron RS 25259, RS 25259 197, extracted fromDrugs in R&D, Oct. 1999, vol. 2, No. 4, pp. 251-252.
Piraccini, Gaia et al., An Interesting 5-HT3Receptor Antagonist Antiemetic for Patients Undergoing Chemotherapy-Based Conditioning Regimens?, extracted fromBlood, Nov. 16, 2001, vol. 98, No. 11, part 2, p. 350b, abstract No. 5169.
Stacher, Georg, Palonosetron Helsinn, extracted fromCurrent Opinion in Investigational Drugs, Oct. 2002, vol. 3, No. 10, pp. 1502-1507.
Navari, Rudolph M., Pathogenesis-Based Treatment of Chemotherapy-Induced Nausea and Vomiting—Two New Agents, extracted fromJournal of Supportive Oncology, 2003, vol. 1(2), pp. 89-103.
Michael J. Pikal, “Freeze Drying”, Encyclopedia of Pharmaceutical Technology, Third Edition, Jan. 2007, pp. 1824-1825, vol. 3, Informa Pharmaceuticals & Healthcare.
Oppostion Brief filed by Dr. Reddy's Laboratories (UK) Limited, opposition to European Patent No. 1601359 B1, Jul. 7, 2009.
Photolytic and oxidative degradation of an antiemetic agent, RG 12915 (Won C. M. Et al, International Journal of Pharmaceutics 121 (1995) 95-105 (1995).
Palonosetron: a phase II dose ranging study to assess over a 7 day period the single dose pharmacokinetic profile of palonosetron in patients receiving highly emetogenic chemotherapy. Piraccini G et al., Proc. Am. Soc. Clin. Oncol 2002 21 Abs 449 (2002).
Formulation and administration techniques to minimize injection pain and tissue damage associated with parenteral products. Larry A. Gatlin; Carol A Brister Gatlin, [from Injectable Drug Development: Techniques to Reduce Pain and Irritation [Edited by Pramod K. Gupta, Gayle A. Brazeau; Published by Informa Health Care (original copyright of 1999 by Interpharma Press), 1999; ISBN 1574910957, 9781574910957)], p. 401-421.
Parenteral Dosage Forms. Joanne Broadhead. [from Part 11—Early drug development, Pharmaceutical preformulation and formulation: a practice guide from candidate drug selection to commercial dosage form [Edited by Mark Gibson; Published by Interpharma Press, 2001; ISBN 1574911201, 9781574911206)], p. 331-353.
Opposition Brief filed by Tecnimede Sociedade Tecnico-Medicinal S.A., opposition to European Patent No. 1601359 B1, Jul. 8, 2009.
Response brief filed by Helsinn Healthcare S.A. dated Jul. 13, 2007, in response to the communication pursuant to Art. 96(2) EPC of Jan. 3, 2007 regarding Serial No. 04 706 657.6-2123.
European Patent Office official communication dated Jul. 19, 2006 regarding Serial No. 04 706 657.6.
Response of Helsinn Healthcare S.A. dated Nov. 29, 2006 regarding EPO official communication dated Jul. 19, 2006.
Lachman et al., The Theory and Practice of Industrial Pharmacy, 1986, third edition, pp. 652-784.
Summary of Product Characteristics for Aloxi 250.
Declaration of Valentino J. Stella, Ph.D.
Opposition Brief filed by Martin Paul White, opposition to European Patent No. 1601359 B1, Jul. 8, 2009.
Wong et al. (1995), in British Journal of Pharmacology, vol. 114, pp. 851-859 and Eglen et al. (1995), in British Journal of Pharmacology, vol. 114, pp. 860-866.
Cover page and pp. 642-644 and 783-784 of The Theory and Practice of Industrial Pharmacy, Third Edition, Lea and Febiger (1986).
Cover page and pp. 514-515 of Modern Pharmaceutics, Second Edition, Marcel Dekker (1990).
Cover page and pp. 142-143 of Pharmaceutical Dosage Forms: Parenteral Medications vol. 1, Second Edition, Marcel Dekker (1992).
Scientific Discussion from the European Public Assessment Report for Aloxi (Palonosetron Hydrochloride).
Kranke et al. 2007, “Recent advances, trends and economic considerations in . . . ” Expert Opinion Pharmacother., 8 (18): 3217-3235).
Morrow et al. 1995, Progress in reducing nausea and emesis. Comparisons of ondansetron, granisetron, and tropisetron. Cancer, vol. 76 No. 3 pp. 343-357.
Daniele Bonadeo, “Supplemental Declaration of Daniele Bonadeo 37 C.F.R. 1.132”, U.S. Appl. No. 11/388,270, Jun. 8, 2009.
Chaitow, 1990, 3 pages.
USPTO Office Action, U.S. Appl. No. 11/388,268, Filing Date Mar. 24, 2006, Mail Date Mar. 29, 2010.
USPTO Office Action, U.S. Appl. No. 11/129,839, Mail Date Jan. 15, 2010.
Israili, Zafar H., Clinical Pharmacology of Serotonin Receptor Type-3 (5-HT3) Antagonists, Curr. Med. Chem.—Central Nervous System Agents, 2001, 1, 171-199.
USPTO Office Action, U.S. Appl. No. 11/201,035, Mail Date Aug. 19, 2009.
Response of Helsinn Healthcare to opposition of EP Serial No. 04 706 657.6 dated Feb. 11, 2010.
Annex 1 (Statement of Waldo Mossi, Ph.D.) to Response of Helsinn Healthcare to opposition of EP Serial No. 04 706 657.6 dated Feb. 11, 2010.
Annex 2 to Response of Helsinn Healthcare to opposition of EP Serial No. 04 706 657.6 dated Feb. 11, 2010.
Annex 3 to Response of Helsinn Healthcare to opposition of EP Serial No. 04 706 657.6 dated Feb. 11, 2010.
6thEdition, Handbook of Pharmaceutical Excipients (2009), pp. 247-250n (RPS Publishing).
Bonadeo Daniele
Braglia Enrico
Braglia Riccardo
Calderari Giorgio
Cannella Roberta
Arnall Golden & Gregory LLP
Gembeh Shirley V
Hartley Michael G
Helsinn Healthcare S.A.
Roche Palo Alto LLC
LandOfFree
Liquid pharmaceutical formulations of palonosetron does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Liquid pharmaceutical formulations of palonosetron, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liquid pharmaceutical formulations of palonosetron will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2634250